Future potential of thymidylate syntase inhibitors in cancer therapy

Expert Opinion on Investigational Drugs

Volumn 11, Issue 12, 2002, Pages 1775-1787

  Lehman, Norman L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifolates; Cancer treatment; Chemotherapy; Fluoropyrimidines; Thymidylate synthase inhibitors

Indexed keywords

10 DEAZAAMINOPTERIN; 10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; 2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; AMINOPTERIN; BW 1843 U89; CAPECITABINE; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; DNA; DRUG METABOLITE; FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; HOMOFOLIC ACID; LOMETREXOL; METESIND GLUCURONATE; METHOTREXATE; METHYLENETETRAHYDROFOLIC ACID; NB 1011; NOLATREXED; PLEVITREXED; PRODRUG; RALTITREXED; TEGAFUR; THYMIDINE PHOSPHATE; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; TRIMETREXATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR;

BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CANCER SURGERY; CATALYSIS; COLORECTAL CANCER; DNA SYNTHESIS; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; ENZYME BINDING; ENZYME INHIBITION; ENZYME SUBSTRATE; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG CARCINOMA; MESOTHELIOMA; METABOLITE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NUCLEOSIDE TRANSPORT; PHARMACOGENETICS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG EFFECT; NEOPLASM;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FOLIC ACID ANTAGONISTS; HUMANS; NEOPLASMS; PHARMACOGENETICS; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE;

EID: 0036906795     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.12.1775     Document Type: Review

References (123)

1. CARRERAS CW. SANTI DV: The catalytic mechanism and structure of thymidylate synthase. Ann. Rev. Biochem. (1995) 64:721-762.
2. NEVINS JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science (1992) 258:424-429.
3. FARBER S, DIAMOND LK, MERCER RD et al.: Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N. Engl. J. Med. (1948) 238:787-793.
4. BURCHENAL FH, KARNOFSKY DA, SOUTHAM CM et al.: Clinical experience with the 4-amino derivatives of pteroylglutamic acid and 2,6-diaminopurine in the treatment of neoplastic disease. Am. J. Med. (1949) 7:420.
5. ALLEGRA CJ, CHABNER BA, DRAKE JC, LUTZ R, RODBARD D, JOLIVET J: Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J. Biol. Chem. (1985) 26:9720-9726.
6. ALLEGRA CJ, DRAKE JC, JOLIVET J, CHABNER BA: Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Nat. Acad. Sci. USA (1985) 82:4881-4885.
7. HERTZ R, LEWIS J Jr, LIPSETT MB: Five years experience with the chemotherapy of metastatic choriocarcinoma and related trophoblsatic tumors in women. Amer. J. Obstet. Gynec. (1961) 82:631-640.
8. KAMEN BA, COLE PD, BERTINO JR: Folate antagonists. In: Cancer Medicine (5th edn). Kufe DW, Pollock RE, Weichel RR et al. (Eds), BC Decker, Inc., Hamilton, Ontario, Canada (2000).
9. FEAGAN BJ, ROCHON J, FEDORAK RN et al.: Methotrexate for the treatment of Crohn's disease. N. Engl. J. Med. (1995) 332:292-297.
10. BORSA J, WHITMORE GF: Cell killing studies on the mode of action of methotrexate on L-cells in vitro. Cancer Res. (1969) 29:737-744.
11. COHEN SS: On the nature of thymineless death. Ann. NY Acad. Sci. (1971) 186:292-301.
12. CURTIN NJ, HARRIS AL, AHERNE GW: Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res. (1991) 51:2346-2352.
13. KWOK JB, TATTERSALL MH: Inhibition of 2-desamino-2-methyl-10-propagyl-5,8-dide azafolic acid cytotoxicity by 5,10-dideaztetrahydrofolate in L1210 cells with decrease in DNA fragmentation and deoxyadenosine triphosphate pools. Biochem. Pharmacol. (1991) 42:507-513.
14. SMITH SG, LEHMAN NL, MORAN RG: Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Cancer Res. (1993) 53:5697-5706.
15. HOUGHTON JA, HARWOOD FG, TILLMAN DM: Thymineless death in colon carcinoma cells is mediated via Fas signalling. Proc. Natl. Acad. Sci. USA (1997) 94:8144-8149.
16. HEIDELBERGER C, CHAUDHURI NK, DANNEBERG P et al.: Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature (1957) 179:663-666.
17. DANENBERG PV, DANENBERG KD: Effect of 5, 10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism. Biochemistry (1978) 17:4018-4022.
18. GLAZER R, HARTMAN K: The effect of 5-fluorouracil on the synthesis and methylation of low molecular weight nuclear RNA in L1210 cells. Mol. Pharmacol. (1980) 17:245-249.
19. LENZ HJ, MANNO DJ, DANENBERG KD, DANENBERG PV. Incorporation of 5-fluorouracil into U2 and U6 SN3RNA inhibits mRNA precursor splicing. J. Biol. Chem. (1994) 269:31962-31968.
20. SIERAKOWSKA H, SHUKLA RR, DOMINSKI Z, KOLE R. Inhibition of pre-mRNA splicing by 5-fluoro-, 5-chloro-, and 5-bromouridine. J. Biol. Chem. (1989) 264:19185-19191.
21. KANAMARU R, KAKUTA H, SATO T, ISHIOKA C, WAKUI A: The inhibitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L1210 cells in vitro. Cancer Chemother. Pharmacol. (1986) 17:43-46.
22. DOLNICK BJ, PINK JJ. Effects of 5-fluorouracil on dihydrofolate reductase and dihydrofolate reductase mRNA from methotrexate-resistant KB cells. J. Biol. Chem. (1985) 260:3006-3014.
23. GHOSHAL K, JACOB ST: An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem. Pharmacol. (1997) 53:1569-1575.
24. SCHMITTGEN TD, DANENBERG KD, HORIKOSHI T, LENZ HJ, DANENBERG PV: Effect of 5-fluoro- and 5-bromouracil substitution on the translation of human thymidylate synthase mRNA. J. Biol. Chem. (1994) 269:16269-16275.
25. LÖNN U, LÖNN S: Interaction between 5-fluorouracil and DNA of human colon adenocarcinoma. Cancer Res. (1984) 44:3414-3418.
26. JOHNSTON PG, BEHAN KA, ALLEGRA CJ, DRAKE JC: Fluorouracil: active in ZD1694 (Tomudex)-resistant cell lines with markedly elevated thymidylate synthase levels. J. Natl. Cancer Inst. (1995) 87:1558-1559.
27. PIZZORNO G, HANDSCHUMACHER RE, CHENG YC: Pyrimidine and purine antimetabolites. In: Holland-Frei Cancer Medicine (5th edn). RC Blast Jr, DW Kufe, RE Pollock et al. (Eds), BC Decker, Inc., Hamilton, Ontario, Canada (2000):625-647.
28. SENDEROFF RI, WEBER PA, SMITH DR, SOKOLOSKI TD: Evaluation of antiproliferative agents using a cell-culture model. Invest. Ophthalmol. Vis. Sci. (1990) 31:2572-2578.
29. KEMENY NE, FONG Y: Treatment of liver metastases. In: Holland-Frei Cancer Medicine, (5th edn). RC Blast Jr, DW Kufe, RE Pollock et al. (Eds), BC Decker, Inc., Hamilton, Ontario, Canada (2000):1402-1414.
30. MARGOLESE RG, FISHER B, HORTOBAGYI GN, BLOOMER WD: Neoplasms of the breast. In: Holland-Frei Cancer Medicine, (5th edn). RC Blast Jr, DW Kufe, RE Pollock et al. (Eds). BC Decker, Inc., Hamilton, Ontario, Canada (2000):1735-1822.
31. DAVIES MM, JOHNSTON PG, KAUR S, ALLEN-MERSH TG: Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Clin. Cancer Res. (1999) 5:325-328.
32. PLANTE LT, CRAWFORD EJ, FRIEDKIN M: Enzyme studies with new analogues of folic acid and homofolic acid. J. Biol. Chem. (1967) 242:1466-1476.
33. SIROTNAK FM, DEGRAW JL, SCHMID FA, GOUTAS LJ, MOCCIO DM: New folate analogues of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemother. Pharmacol. (1984) 12:26-30.
34. FRY DW, JACKSON RC: Biological and biochemical properties of new anticancer folate antagonists. Cancer Metastasis Rev. (1987) 5:251-270.
35. ITOH F, RUSSELLO O, AKIMOTO H, BEARDSLEY GP: Novel pyrrolo[2,3-d]pyrimidine antifolate TNP-351: cytotoxic effect on methotrexate-resistant CCRF-CEM cells and inhibition of transformylases of de novo purine biosynthesis. Cancer Chemother. Pharmacol. (1994) 34:273-279.
36. ROUGIER P, PAILLOT B, LAPLANCHE A et al.: 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. Eur. J. Cancer (1997) 33:1789-1793.
37. CASSATA A, PROCOPLO G, ALU M et al.: Capecitabine: indications and future perspectives in the treatment of metastatic colorectal and breast cancer. Tumori (2001) 87:364-371.
38. KEYOMARSI K, SAMET J, MOLNAR G, PARDEE AB: The thymidylate synthase inhibitor ICI D1694 overcomes translational detainment of the enzyme. J. Biol. Chem. (1993) 268:15132-15149.
39. PETERS GJ, BACKUS HH, FREEMANTLE S et al.: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim. Biophys. Acta (2002) 1587:194-205.
40. LACKEY DB, GROZIAK MP, SERGEEVA M et al.: Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. Biochem. Pharmacol. (2001) 61:179-189.
41. LI Q, BOYER C, LEE JY, SHEPARD HM: A novel approach to thymidylate synthase as a target for cancer chemotherapy. Mol. Pharmacol. (2001) 59:446-452.
42. JONES TR, CALVERT AH, JACKMAN AL, BROWN SJ, JONES M, HARRAP KR.: A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice. Eur. J. Cancer (1981) 17:11-19.
43. CALVERT AH, ALISON DL, HARLAND SJ et al.: A Phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB 3717. Clin. Oncol. (1986) 4:1245-1252.
44. MARSHAM PR, HUGHES LR, JACKMAN AL et al.: Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications. J. Med. Chem. (1991) 34:1594-1605.
45. JACKMAN AL, TAYLOR GA, GIBSON W et al.: ICI D1694, a quinazoline antifolate thymidylate synthesis inhibitor that is a potent inihibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. (1991) 51:5579-5586.
46. JACKMAN AL, FARRUGIA DC, GIBSON W et al.: ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer. Eur. J. Cancer (1995) 31A:1277-1282.
47. SPINELLA MJ, BRIGLE KE, SIERRA EE, GOLDMAN ID: Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. J. Biol. Chem. (1995) 270:7842-7849.
48. WESTERHOF GR, JANSEN G, VAN EMMERIK N et al.: Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems. Cancer Res. (1991) 51:5507-5513.
49. ANDERSON RGW, KAMEN BA, ROTHBERG KG, LACEY SW: Potocytosis: sequestration and transport of small molecules by caveolae. Science (1992) 255:410-411.
50. WESTERHOF GR, SCHORNAGEL JH, KATHMANN I et al.: Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol. Pharmacol. (1995) 48:459-471.
51. CUNNINGHAM D, ZALCBERG JR, RATH U et al.: 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorecral Cancer Study Group. Eur. J. Cancer (1995) 31A:1945-1954.
52. KERR D, CUNNINGHAM D, ZALCBERG J et al.: 'Tomudex' (ZD1694) has superior response rate and toxicity profiles compared to 5-fluorouracil and leucovorin (5-FU-LV) in advanced colorectal cancer (CRC): first results of a large international Phase III study. Br. J. Cancer (1995) 72(Suppl. 25):10.
53. CUNNINGHAM D, ZALCBERG JR, RATH U: Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann. Oncol. (1996) 7:96-1965.
54. MAUGHAN TS, JAMES RD, KERR DJ et al.: Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomized trial. Lancet (2002) 359:1555-1563.
55. SMITH I, JONES A, SPIELMANN M et al.: A Phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br. J. Cancer (1996) 74:479-481.
56. BURRIS H, VON HOFF D, BOWEN K et al.: A Phase II trial of ZD1694, a novel thymidylate synthase inhibitor, in patients with advanced non-small cell lung cancer. Annals. Oncol. (1994), 5(Supp. 5):133 (Abstract 244).
57. PAZDUR R, MEROPOL NJ, CASPER ES et al.: Phase II trial of ZD1694 (tomudex) in patients with advanced pancreatic cancer. Invest. New Drugs (1996) 13:355-358.
58. DE JONG MJ, PUNT CJ, SPARREBOOM A: Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. J. Clin. Oncol. (2002) 20:1923-1931.
59. JACKMAN AL, MELIN CJ, KIMBELL R et al.: A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours. Biochim. Biophys. Acta (2002) 1587:215-223.
60. JACKMAN AL, CALVERT AH: Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann. Oncol. (1995) 6:871-881.
61. O'DWYER PJ, LAUB PB, DeMARIA D et al.: Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. Clin. Cancer Res. (1996) 2:1685-1692.
62. CREAVEN PJ, PENDYALA L, MEROPOL NJ et al.: Initial clinical trial and pharmacokinetics of Thymitaq™ (AG337) by 10-day continuous infusion in patients with advanced solid tumors. Cancer Chemother. Pharmacol. (1998) 41:167-170.
63. ROSELL R, CRINO L: Pemetrexed continuation therapy in the treatment of non-small cell lung carcinoma. Semin. Oncol. (2002) 29(2, Suppl. 5):23-29.
64. FIZAZI K, JOHN WJ, VOGELZANG NJ: The emerging role of antifolates in the treatment of malignant pleural mesothelioma. Semin. Oncol. (2002) 29:77-81.
65. DANENBERG PV, MALLI H, SWENSON S: Thymidylate synthase inhibitors. Semin. Oncol. (1999) 26:621-631.
66. TOUROUTOGLOU N, PAZDUR R: Thymidylate synthase inhibitors. Clin. Cancer Res. (1996) 2:227-243.
67. CAPIZZI RL, DECONTI RC, MARSH JC, BERTINO JK: Methotrexate therapy of head and neck cancer: improvement in therapeutic index by the use of leucovorin 'rescue'. Cancer Res. (1970) 30:1782-1788.
68. EVANS RM, LASKIN JD, HAKALA MT: Effects of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res. (1981) 41:3288-3295.
69. FERNANDES DJ, BERTINO JR: 5-Fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyuridylate binding to thymidylate synthase by dihydropteroylpolyglutamates. Proc. Nat. Acad. Sci. USA (1980) 77:5663-5667.
70. JODRELL DI, OSTER W, KERR DJ et al.: A Phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer. Eur. J. Cancer (1994) 30A:950-955.
71. GREM JL, VAN GROENINGEN CJ, ISMAIL AA, JOHNSTON PG, ALEXANDER HR, ALLEGRA CJ: The role of interferon-α as a modulator of fluorouracil and leucovorin. Eur. J. Cancer (1995) 31A:1316-1320.
72. PORTER DJ, CHESTNUT WG, MERRILL BM, SPECTOR T: Mechansim-based inactivation of dihydropyridine dehydrogenase by ethyluracil (776C85). J. Biol. Chem. (1992) 267:5236-5242.
73. LEHMAN NL, DANENBERG PV: Modulation of RTX cytotoxicity by thymidine and dipyridamole in vitro: implications for chemotherapy. Cancer Chemother. Pharmacol. (2000) 45:142-148.
74. WEBER G: Biochemical strategy of cancer cells and the design of chemotherapy; G. H. A. Clowes Memorial Lecture. Cancer Res. (1983) 43:3466-3492.
75. DENTON JE, LUI MS, AOKI T et al.: Enzymology of pyrimidine and carbohydrate metabolism in human colon carcinomas. Cancer Res. (1982) 42:1176-1183.
76. NATSUMEDA Y, PRAJDA N, DONOHUE JP, GLOVER JL, WEBER G: Enzymatic capacities of purine de novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues. Cancer Res. (1984) 44:2475-2479.
77. NATSUMEDA Y, LUI MS, EMRANI J et al.: Purine enzymology of human colon carcinomas. Cancer Res. (1985) 45:2556-2559.
78. ZHEN YS, TANIKI T, WEBER G: Azidothymidine and dipyridamole as biochemical modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells. Oncology Res. (1992) 4:73-78.
79. PRESSACCO J, ERLICHMAN C: Combination studies with 3′-azido-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects. Biochem. Pharmacol. (1993) 46:1989-1997.
80. GREM JL, FISCHER PH: Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole. Cancer Res. (1985) 45:2967-2972.
81. CURTIN NJ, HARRIS AL. Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells. Biochem. Pharmacol. (1988) 37:2113-2120.
82. CHAN TCK, HOWELL SB: Mechanism of synergy between N-phosphon-acetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line. Cancer Res. (1985) 45:3598-3604.
83. JEKUNEN A, VICK J, SANGA R, CHAN TC, HOWELL SB: Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro. Cancer Res. (1992) 52:3566-3571.
84. KUSUMOTO H, MAEHARA Y, ANAI H, KUSUMOTO T, SUGIMACHI K: Potentiation of adriamycin cytotoxicity by dipyridamole against HeLa cells in vitro and sarcoma 180 cells in vivo. Cancer Res. (1988) 48:1208-1212.
85. TURNER RN, CURTIN NJ: Dipyridamole increases VP16 growth inihibition, accumulation and retention in parental and multidrug-resistant CHO cells. Br. J. Cancer (1996) 73:856-860.
86. MUGGIA FM, SLOWIACZEK P, TATTERSALL MHN: Characterization of conditions in which dipyridamole enhances methotrexate toxicity in L1210 cells. Anticancer Res. (1987) 7:161-166.
87. ASOH KI, SABURI Y, SATO SI, NOGAE I, KOHNO K, KUWANO M: Potentiation of some anticancer agents by dipyridamole against drug-sensitive and drug-resistant cancer cell lines. Jpn. J. Cancer Res. (1989) 80:475-481.
88. HOLDEN L, HOFFBRAND AV, TATTERSALL MHN: Thymidine concentrations in human sera: variations in patients with leukemia and megaloblastic anemia. Eur. J. Cancer (1980) 16:115-121.
89. HOWELL SB, MANSFIELD SJ, TAETLE R: Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate. Cancer Chemother. Pharmacol. (1981) 5:221-226.
90. GREM JL: Biochemical modulation of fluorouracil by dipyridamole: preclinical and clinical experience. Semin. Oncol. (1992) 19(2, Suppl. 3):56-65.
91. KOHNE CH, HIDDEMANN W, SCHULLER J et al.: Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. J. Clin. Oncol. (1995) 13:1201-1208.
92. BURCH PA, GHOSH C, SCHROEDER G et al.: Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C, and oral dipyridamole in advanced measurable pancreatic cancer: a North Central Cancer Treatment Group Trial. Am. J. Clin. Oncol. (2000) 23:534-537.
93. NOMURA M, NAKANO S, KUDOU J, ISHIBASHI O, NIHO Y: Successful treatment of advanced gastric cancer with multiple liver metastasis by combination chemotherapy using mitomycin C, 5-fluorouracil, and high-dose leucovorin: a case report. Jpn. J. Cancer Chemother. (1990) 17:2097-2100.
94. MITSUGI K, YASUTAKE T, ETOH T et al.: Successful treatment of recurrent multiple lung metastasis from colon cancer with combination chemotherapy using methotrexate, 5-fluorouracil, and high-dose leucovorin: a case report. Jpn. J. Cancer Chemother. (1993) 20:2387-2390.
95. SUGIMORI H, NAKANO S, CHIFU Y et al.: 5-Fluorouracil + low-dose leucovorin and cisplatin sequential chemotherapy with dipyridamole for advanced nonresectable squamous cell carcinoma of the lung: a case report. Jpn. J. Cancer Chemother. (1993) 20:287-290.
96. CHAKRAVARTHY A, ABRAMS RA, YEO CJ et al.: Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. Int. J. Radiat. Oncol. Biol. Phys. (2000) 48:1089-1096.
97. TODD KE, GLOOR B, LANE JS, ISACOFF WH, REBER HA: Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole. J. Gastrointest. Surg. (1998) 2:159-166.
98. CHEN HX, BAMBERGER U, HECKEL A, GUO X, CHENG YC: BIBW 22, a dipyridamole analogue, acts a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleotide transport. Cancer Res. (1993) 53:1974-1977.
99. JANSEN WJ, PINEDO HM, KUIPER CM et al.: Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole. Ann. Oncology (1994) 5:733-739.
100. GOEL R, CLEARY SM, HORTON C et al.: Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole. J. Clin. Oncol. (1989) 7:262-269.
101. PRESSACCO J, MITROVSKI B, ERLICHMAN C, HEDLEY DW: Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res. (1995) 55:1505-1508.
102. BOYER CR, KARJIAN PL, WAHL GM, PEGRAM M, NEUTEBOOM ST: Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011. Anti-Cancer Drugs (2002) 13:29-36.
103. HORIKOSHI T, DANENBERG KD, STADLBAUER THW et al.: Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res. (1991) 52:108-116.
104. JOHNSTON P G, LENZ HJ, DANENBERG KD et al.: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. (1995) 55:1407-1412.
105. LENZ HJ, LEICHMAN CG, DANENBERG KD et al.: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J. Clin. Oncol. (1996) 14:176-182.
106. LINK KH, KORNMANN M, BUTZER U et al.: Thymidylate synthase quantitation and in vitro chemosensitiviry testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy. Cancer (2000) 89:288-296.
107. SALONGA D, DANENBERG KD, JOHNSON M et al.: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. (2000) 6:1322-1327.
108. METZGER R, DANENBERG K, LEICHMAN CG et al.: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin. Cancer Res. (1998) 4:2371-2376.
109. DRAKE JC, ALLEGRA CJ, MORAN RG, JOHNSTON PG: Resistance to Tomudex (ZD1694): multifactoral in human breast and colon carcinoma cell lines. Biochem. Pharmacol. (1996) 51:1349-1355.
110. ROTHEM L, IFERGAN I, KAUFMAN Y, PRIEST DG, JANSEN G, ASSARA F: Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukemia cell lines. Biochem. J. (2002) 367:741-750.
111. RHEE MS, WANG Y, NAIR MG, CALIVAN J: Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res. (1993) 53:2227-2230.
112. LI WW, WALTHAM M,TONGW, SCHWEITZER BI, BERTINO JR: Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate (MTX). Adv. Exp. Med. Biol. (1993) 338-635-638.
113. MINI E, BIONDI C, MORGANTI M et al.: Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors. Oncol. Res. (1999) 11:437-445.
114. MIOTTI S, CANEVARI S, MENARD S et al.: Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int. J. Cancer (1987) 39:297-303.
115. BUENO R, APPASANI K, MERCER H, LESTER S, SUGARBAKER D: The alpha folate receptor is highly activated in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. (2001) 121:225-233.
116. WEITMAN SD, LARK RH, CONEY LR et al.: Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. (1992) 52:3396-3401.
117. SCHENA M, SHALON D, DAVIS RW, BROWN PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (1995) 270:467-470.
118. CARTWRIGHT CP: Pharmacogenetics: the Dx perspective. Expert. Rev. Mol. Diagn. (2001) 1:371-376.
119. O'DWYER ME, DRUKER BJ: The role of the tyrosine kinase inhibitor ST1571 in the treatment of Cancer. Curr. Cancer Drug Targets (2001) 1:49-57.
120. HARRIES M, SMITH I: The development and clinical use of trastuzumab (Herceptin). Endocr. Relat. Cancer (2002) 9:75-85.
121. CHESON BD: Hematologic malignancies: new developments and future treatments. Semin. Oncol. (2002) 29(4, Suppl. 13): 33-45.
122. FONTANA JA, RISHI AK: Classical and novel retinoids: their targets in cancer therapy. Leukemia (2002) 16:463-472.
123. ELLIOT PJ, ROSS JS: The proteosome: a new target for novel drug therapies. Am. J. Clin. Pathol. (2001) 116:637-646.